Tobey J Betthauser

List of Publications by Year
in descending order

69 papers	1,117 citations	430874 18 h-index	434195 31 g-index
86 all docs	86 docs citations	86 times ranked	1573 citing authors

#	Article	IF	Citations
1	In Vivo Characterization and Quantification of Neurofibrillary Tau PET Radioligand ^{18}F-MK-6240 in Humans from Alzheimer Disease Dementia to Young Controls. Journal of Nuclear Medicine, 2019, 60, 93-99.	5.0	161
2	Amyloid and tau imaging biomarkers explain cognitive decline from late middle-age. Brain, 2020, 143, 320-335.	7.6	100
3	An examination of a novel multipanel of CSF biomarkers in the Alzheimer's disease clinical and pathological continuum. Alzheimer's and Dementia, 2021, 17, 431-445.	0.8	80
4	Measuring longitudinal cognition: Individual tests versus composites. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 74-84.	2.4	69
5	The effects of normal aging on amyloid-β deposition in nondemented adults with Down syndrome as imaged by carbon 11–labeled Pittsburgh compound B. Alzheimer's and Dementia, 2016, 12, 380-390.	0.8	65
6	In Vivo Comparison of Tau Radioligands ^{18}F-THK-5351 and ^{18}F-THK-5317. Journal of Nuclear Medicine, 2017, 58, 996-1002.	5.0	54
7	Longitudinal changes in amyloid positron emission tomography and volumetric magnetic resonance imaging in the nondemented Down syndrome population. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 9, 1-9.	2.4	49
8	Cerebrospinal fluid ratios with Aβ_{42} predict preclinical brain β-amyloid accumulation. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 2, 27-38.	2.4	44
9	Amyloid duration is associated with preclinical cognitive decline and tau PET. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12007.	2.4	43
10	*KLOTHO* heterozygosity attenuates *APOE4* -related amyloid burden in preclinical AD. Neurology, 2019, 92, e1878-e1889.	1.1	40
11	Hypertension and obesity moderate the relationship between β-amyloid and cognitive decline in midlife. Alzheimer's and Dementia, 2019, 15, 418-428.	0.8	38
12	Divergent Cortical Tau Positron Emission Tomography Patterns Among Patients With Preclinical Alzheimer Disease. JAMA Neurology, 2022, 79, 592.	9.0	29
13	Human brain imaging of nicotinic acetylcholine $\alpha 4\beta 2$* receptors using [^{18}F]Nifene: Selectivity, functional activity, toxicity, aging effects, gender effects, and extrathalamic pathways. Journal of Comparative Neurology, 2018, 526, 80-95.	1.6	26
14	Alzheimer-Like Pattern of Hypometabolism Emerges with Elevated Amyloid-β Burden in Down Syndrome. Journal of Alzheimer's Disease, 2017, 61, 631-644.	2.6	23
15	The use of Centiloids for applying [^{11}C]PiB classification cutoffs across region-of-interest delineation methods. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 332-339.	2.4	22
16	Imaging neurodegeneration in Down syndrome: brain templates for amyloid burden and tissue segmentation. Brain Imaging and Behavior, 2019, 13, 345-353.	2.1	21
17	Validity Evidence for the Research Category, "Cognitively Unimpaired – Declining," as a Risk Marker for Mild Cognitive Impairment and Alzheimer's Disease. Frontiers in Aging Neuroscience, 2021, 13, 688478.	3.4	21
18	Sex differences in off-target binding using tau positron emission tomography. NeuroImage: Clinical, 2021, 31, 102708.	2.7	21

#	Article	IF	Citations
19	PET-BIDS, an extension to the brain imaging data structure for positron emission tomography. Scientific Data, 2022, 9, 65.	5.3	20
20	First-in-Human Evaluation of ^{18}F-Mefway, a PET Radioligand Specific to Serotonin-1A Receptors. Journal of Nuclear Medicine, 2014, 55, 1973-1979.	5.0	19
21	Amyloid accumulation in Down syndrome measured with amyloid load. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12020.	2.4	19
22	Proper names from story recall are associated with beta-amyloid in cognitively unimpaired adults at risk for Alzheimer's disease. Cortex, 2020, 131, 137-150.	2.4	17
23	Serial position effects in the Logical Memory Test: Loss of primacy predicts amyloid positivity. Journal of Neuropsychology, 2021, 15, 448-461.	1.4	16
24	[18F]Nifene test-retest reproducibility in first-in-human imaging of $\alpha 4\beta 2$* nicotinic acetylcholine receptors. Synapse, 2017, 71, e21981.	1.2	13
25	Amyloid and Tau PET Imaging of Alzheimer Disease and Other Neurodegenerative Conditions. Seminars in Ultrasound, CT and MRI, 2020, 41, 572-583.	1.5	12
26	Human biodistribution and dosimetry of [18 F]nifene, an $\alpha 4\beta 2$* nicotinic acetylcholine receptor PET tracer. Nuclear Medicine and Biology, 2017, 55, 7-11.	0.6	11
27	AD molecular: Imaging tau aggregates with positron emissions tomography. Progress in Molecular Biology and Translational Science, 2019, 165, 107-138.	1.7	10
28	Characterization of the radiosynthesis and purification of [18F]THK-5351, a PET ligand for neurofibrillary tau. Applied Radiation and Isotopes, 2017, 130, 230-237.	1.5	9
29	Cohort study of electroencephalography markers of amyloid-tau-neurodegeneration pathology. Brain Communications, 2020, 2, fcaa099.	3.3	9
30	Principal components from untargeted cerebrospinal fluid metabolomics associated with Alzheimer's disease biomarkers. Neurobiology of Aging, 2022, 117, 12-23.	3.1	7
31	In vivo staging of regional amyloid progression in healthy middle-aged to older people at risk of Alzheimer's disease. Alzheimer's Research and Therapy, 2021, 13, 178.	6.2	6
32	Association of Neighborhood-Level Disadvantage With Neurofibrillary Tangles on Neuropathological Tissue Assessment. JAMA Network Open, 2022, 5, e228966.	5.9	5
33	Cerebrovascular stiffness and flow dynamics in the presence of amyloid and tau biomarkers. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12253.	2.4	4
34	CSF sphingomyelin metabolites in Alzheimer's disease, neurodegeneration, and neuroinflammation. Alzheimer's and Dementia, 2021, 17, .	0.8	4
35	IC-P-018: VERBAL FLUENCY MEASURES ARE ASSOCIATED WITH ALZHEIMER'S DISEASE BIOMARKERS IN CLINICALLY UNIMPAIRED LATE MIDDLE-AGED ADULTS FROM THE WISCONSIN REGISTRY FOR ALZHEIMER'S PREVENTION. Alzheimer's and Dementia, 2018, 14, P23.	0.8	2
36	Amyloid time: Quantifying the onset of abnormal biomarkers and cognitive impairment along the Alzheimer's disease continuum. Alzheimer's and Dementia, 2021, 17, .	0.8	2

#	Article	IF	Citations
37	Synaptic vesicle protein SV2A imaging with [11C]UCBâ€‘ as a novel biomarker of neurodegeneration in Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e037789.	0.8	1
38	MKâ€‘6240 imaging features, cognitive associations in preclinical Alzheimerâ€™s disease and a case with imagingâ€‘toâ€‘postmortem correlates. Alzheimer's and Dementia, 2020, 16, e043217.	0.8	1
39	Predicting the time to tau onset in Down syndrome using amyloid chronicity. Alzheimer's and Dementia, 2020, 16, e046060.	0.8	1
40	The relationship of glucose-stimulated insulin secretion to cerebral glucose metabolism and cognition in healthy middle-aged and older adults. Neurobiology of Aging, 2021, 105, 174-185.	3.1	1
41	CSF amyloid, tau, and neurodegeneration biomarkers are associated with longitudinal cognitive decline in preclinical AD. Alzheimer's and Dementia, 2021, 17, .	0.8	1
42	Lateralized tau deposition and speech, language, and cognition: A descriptive case report. Alzheimer's and Dementia, 2021, 17, .	0.8	1
43	O5-01-05: Tau and amyloid imaging in presymptomatic and symptomatic Alzheimer's disease with [F-18]THK5117 and [C-11]PiB: A multimodal imaging study. , 2015, 11, P314-P314.		0
44	P1-274: Patterns of In-Vivo Preclinical TAU and Amyloid Burden Using [F-18]THK5351 and [C-11]PIB. , 2016, 12, P521-P522.		0
45	ICâ€‘Pâ€‘195: Patterns of inâ€‘Vivo Preclinical TAU and Amyloid Burden Using [Fâ€‘18]THK5351 and [Câ€‘11]PIB. Alzheimer's and Dementia, 2016, 12, P141.	0.8	0
46	[O2â€“02â€“06]: ALZHEIMERâ€‘LIKE PATHOPHYSIOLOGICAL CHANGES IN THE NONâ€‘DEMENTED DOWN SYNDROME POPULATION. Alzheimer's and Dementia, 2017, 13, P554.	0.8	0
47	O2â€‘03â€‘05: VERBAL FLUENCY MEASURES ARE ASSOCIATED WITH ALZHEIMER'S DISEASE BIOMARKERS IN CLINICALLY UNIMPAIRED, LATE MIDDLEâ€‘AGED ADULTS FROM THE WISCONSIN REGISTRY FOR ALZHEIMER'S PREVENTION. Alzheimer's and Dementia, 2018, 14, P617.	0.8	0
48	O3â€‘04â€‘06: TAU IMAGING WITH [Fâ€‘18]MK6240 ACROSS THE AD SPECTRUM: ASSOCIATIONS WITH AMYLOID AND COGNITIVE STATUS. Alzheimer's and Dementia, 2018, 14, P1021.	0.8	0
49	P1â€‘126: PRACTICAL CONSIDERATIONS FOR STATIC PET IMAGING OF [18F]MKâ€‘6240. Alzheimer's and Dementia, 2018, 14, P319.	0.8	0
50	ICâ€‘Pâ€‘004: AMYLOID BURDEN AND CORTICAL ATROPHY IN NONâ€‘DEMENTED DOWN SYNDROME. Alzheimer's and Dementia, 2018, 14, P16.	0.8	0
51	ICâ€‘Pâ€‘200: PRACTICAL CONSIDERATIONS FOR STATIC PET IMAGING OF [18F]MKâ€‘6240. Alzheimer's and Dementia, 2018, 14, P164.	0.8	0
52	O2â€‘06â€‘04: DOES Î²â€‘AMYLOID BURDEN PREDICT COGNITIVE DECLINE STATUS IN ADULTS AT RISK FOR ALZHEIMER'S DISEASE?. Alzheimer's and Dementia, 2018, 14, P632.	0.8	0
53	P1â€‘445: AMYLOID BURDEN AND CORTICAL ATROPHY IN NONâ€‘DEMENTED DOWN SYNDROME. Alzheimer's and Dementia, 2018, 14, P484.	0.8	0
54	F4. Alzheimerâ€™s Disease Biomarkers are Associated With Altered White Matter Microstructure. Biological Psychiatry, 2018, 83, S238.	1.3	0

#	Article	IF	Citations
55	IC‐P‐117: RETROSPECTIVE COGNITIVE DECLINE IS ASSOCIATED WITH NEUROFIBRILLARY TANGLES AND BETA‐AMYLOID PLAQUES MEASURED BY [F‐18]MK‐6240 AND [C‐11]PIB IN LATE‐MIDDLE AGED PERSONS CLINICALLY UNIMPAIRED AT BASELINE. Alzheimer's and Dementia, 2019, 15, P99.	0.8	0
56	IC‐06‐01: ASSESSMENT OF LONGITUDINAL AMYLOID LOAD CHANGE IN DOWN SYNDROME. Alzheimer's and Dementia, 2019, 15, P10.	0.8	0
57	In vivo amyloid progression in healthy middle‐aged to older people at risk of Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e040789.	0.8	0
58	Associations between an abbreviated CAIDE score and amyloid chronicity. Alzheimer's and Dementia, 2020, 16, e044659.	0.8	0
59	PET differences between cognitively unimpaired stable and declining subtypes: Multiple approaches show higher amyloid and tau among those with sub‐clinical cognitive decline. Alzheimer's and Dementia, 2020, 16, e046316.	0.8	0
60	Association of cerebral white matter disease with cardiovascular risk factors, amyloid accumulation, and cognition. Alzheimer's and Dementia, 2020, 16, e046518.	0.8	0
61	Associations between lifestyle risk, β‐amyloid, tau, and cognition in late mid‐life. Alzheimer's and Dementia, 2020, 16, e046562.	0.8	0
62	Chronicity of amyloid: Methods for estimating amyloid onset and clinical research applications. Alzheimer's and Dementia, 2020, 16, e039782.	0.8	0
63	Relationship of insulin resistance and glucose to tau PET positivity. Alzheimer's and Dementia, 2021, 17, .	0.8	0
64	Association of anticholinergic medication and AD biomarkers among cognitively normal late middle‐age adults: Results from the Wisconsin Registry for Alzheimer's Prevention (WRAP). Alzheimer's and Dementia, 2021, 17, .	0.8	0
65	Age of amyloid onset, but not amyloid accumulation rate, differs across APOE‐ε4 carriers vs. non‐carriers in three cohorts and three methods. Alzheimer's and Dementia, 2021, 17, .	0.8	0
66	Associations in Alzheimer's disease between intracranial vascular metrics from 4D‐flow MRI and β‐amyloid and tau PET. Alzheimer's and Dementia, 2021, 17, .	0.8	0
67	Amyloid status is associated with deficits in connected speech language. Alzheimer's and Dementia, 2021, 17, .	0.8	0
68	Examining differences across sleep profiles in late middle‐aged adults: Results from the Wisconsin Registry for Alzheimer's Prevention (WRAP). Alzheimer's and Dementia, 2021, 17, .	0.8	0
69	Neurite density and free water concentration are associated with synaptic density in the hippocampus as assessed through NODDI and [C‐11]UCB‐J PET. Alzheimer's and Dementia, 2021, 17, .	0.8	0